Abstract: Provided are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein Y, CY, R1, R3, R4, R5, R6, R2a, R2b, RMa, RMb, and the subscripts m, n, and q are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treatment of cancer. Also provided are pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. Also provided are methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

Abstract: A method of providing visual information to a user includes receiving a first frame having a first resolution, downscaling the first frame to a second resolution, the second resolution being lower resolution than the first resolution, receiving a second frame having the first resolution, downscaling the second frame to the second resolution, comparing the first frame at the second resolution to the second frame at the second resolution to create a second resolution motion vector field, seeding a seeded first resolution motion vector field, comparing the first frame at the first resolution to the second frame at the first resolution to refine the seeded first resolution motion vector field to create a refined first resolution motion vector field, and applying a blur filter to the first frame at the first resolution based on the refined first resolution motion vector field to create a filtered first frame.

Abstract: The present invention is directed to pyrazolopyrimidine compounds of the general structural formula I: which may be useful as therapeutic agents for the treatment of disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating cardiovascular and cerebrovascular diseases, such as hypertension, chronic kidney disease and heart failure, and neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Abstract: A method of providing visual information to a user includes receiving a first frame having a first resolution, downscaling the first frame to a second resolution, the second resolution being lower resolution than the first resolution, receiving a second frame having the first resolution, downscaling the second frame to the second resolution, comparing the first frame at the second resolution to the second frame at the second resolution to create a second resolution motion vector field, seeding a seeded first resolution motion vector field, comparing the first frame at the first resolution to the second frame at the first resolution to refine the seeded first resolution motion vector field to create a refined first resolution motion vector field, and applying a blur filter to the first frame at the first resolution based on the refined first resolution motion vector field to create a filtered first frame.

Abstract: The present invention is directed to pyrazolopyrimidine compounds of the general structural formula I: which may be useful as therapeutic agents for the treatment of disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating cardiovascular and cerebrovascular diseases, such as hypertension, chronic kidney disease and heart failure, and neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Abstract: There is disclosed a cooling arrangement for a turbine casing (50) of a gas turbine engine (10). The cooling arrangement comprises a first cooling duct (203) that is at least partly within a second cooling duct (204). The first cooling duct is for a first cooling fluid flow and the second cooling duct is for a second cooling fluid flow which flows around the first cooling duct.

Abstract: The present invention is directed to pyrazolopyrimidine compounds of the general structural formula I: which may be useful as therapeutic agents for the treatment of disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating cardiovascular and cerebrovascular diseases, such as hypertension, chronic kidney disease and heart failure, and neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Abstract: There is disclosed a cooling arrangement for a turbine casing (50) of a gas turbine engine (10). The cooling arrangement comprises a first cooling duct (203) that is at least partly within a second cooling duct (204). The first cooling duct is for a first cooling fluid flow and the second cooling duct is for a second cooling fluid flow which flows around the first cooling duct.

Abstract: Described is an improved storage architecture. In a particular aspect an improved storage architecture with increased throughput to Ethernet storage modules due to elimination of data path handling from a main control CPU is set forth. Other method and apparatus are described therein, including a scalable Ethernet storage module particularly suited for usage with the improved storage architecture described herein.

Abstract: Methods and systems for hardware-accelerated packet multicasting are provided. According to one embodiment, a first multicast packet to be multicast to a first multicast destination is received by a virtual routing system. The multicast packet is caused to be transmitted to the multicast destination by: (i) directing the multicast packet to a first VR of multiple VRs instantiated within the virtual routing system by selecting the first VR from among the multiple VRs to multicast the multicast packet; (ii) configuring the virtual routing system to use a routing context associated with the selected VR in connection with processing of the multicast packet; (iii) reading at least a portion of the multicast packet from one of multiple multicast address spaces associated with the selected VR; and (iv) forwarding the multicast packet to the first multicast destination. Similar steps are then performed for a second multicast packet.

Abstract: The present invention is directed to pyrazolopyrimidine compounds which may be useful as therapeutic agents for the treatment of disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating cardiovascular and cerebrovascular diseases, such as hypertension, chronic kidney disease and heart failure, and neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Abstract: Various embodiments relating to selecting a motion vector in a hardware encoder are disclosed. In one example, a plurality of candidate predicted motion vectors are selected, and a plurality of motion searches are performed in an image region surrounding each candidate predicted motion vector to produce a plurality of resulting motion vectors, wherein each resulting motion vector has an initial cost score determined using a corresponding candidate predicted motion vector. After an actual predicted motion vector becomes available, the initial cost score of each resulting motion vector is re-scored using the actual predicted motion vector to produce an updated cost score, and video data is encoded using a motion vector selected from the plurality of resulting motion vectors based on the updated cost score of that motion vector.

Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more compounds of Formula (I), and methods for using the compounds of Formula (I) for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

Abstract: Methods and systems for providing IP services in an integrated fashion are provided. According to one embodiment, a flow cache is established having multiple entries each identifying one of multiple VR flows through a VR-based network device and corresponding forwarding state information. A packet is received at an input port of a line interface module of the network device and forwarded to a VRE. Flow-based packet classification is performed by the VRE. An attempt is made to retrieve an entry of the flow cache based on a result of the flow-based packet classification. On a flow cache hit, one or more appropriate packet transformations are identified for application to the packet and it is determined whether to process the packet with a VSE based on the corresponding forwarding state information. On a flow cache miss, the new VR flow is added to the flow cache by performing flow learning.

Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

Abstract: Described is an improved storage architecture. In a particular aspect an improved storage architecture with increased throughput to Ethernet storage modules due to elimination of data path handling from a main control CPU is set forth. Other method and apparatus are described therein, including a scalable Ethernet storage module particularly suited for usage with the improved storage architecture described herein.

Abstract: An apparatus may include a substrate material. The substrate material may lay substantially planar along a first axis. The apparatus may also include a plurality of punch-outs consisting of the substrate material and fastened to the substrate material. Each punch-out may be to be removed from the substrate material with an application of force upon each punch-out to create an open space in the substrate material. The apparatus may also include a first plurality of linear joints in the substrate material to allow the substrate material to be folded into a box form including at least five sides. The box form includes an inside portion.

Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

Abstract: A bleed valve arrangement for a gas turbine engine comprises a bleed valve housing defining a bleed duct through which a bleed flow may pass in use and a valve within the bleed duct operable between a closed position and an open position. The valve position is continuously variable between the closed position and the open position. The arrangement further comprises an ejection duct downstream of the bleed duct. The arrangement is characterised in that the ejection duct has a greater cross-sectional area than the bleed duct immediately downstream of the bleed duct so that the bleed flow experiences a sudden expansion on passing from the bleed duct into the ejection duct.